There is a lack of nationwide studies examining the epidemiology and comorbidities of psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) in Asian populations. The purpose of this study is to determine the demographics of psoriasis in Korea along with the incidence of cerebro-cardiovascular (CV) comorbidities and to compare these risks between populations with PsA and with PsV. This cohort study identified 15 484 patients with psoriasis among 855 003 subjects in the Korean National Health Insurance Database from 2002 through 2010. The cases were further classified into PsA and PsV. We used hazard ratios (HR) and 95% confidence intervals (CI) from the univariate and age-sex adjusted logistic regression model to assess the risk of comorbidities in patients with PsA and PsV. The annual prevalence of psoriasis increased from 313.2 to 453.5/100 000 people from 2002 through 2010; however, the overall incidence rate for psoriasis slightly decreased (252.7-212.6/100 000 population). Of psoriatic patients, 10.8% had PsA, and after adjusting for age and sex, PsA patients had a significantly higher risk of dyslipidemia than PsV patients (adjusted HR, 1.185; 95% CI, 1.049-1.338). When stratified by age group, subjects aged 20-39 years had a higher risk of stroke and many CV risk factors. In conclusion, the prevalence of psoriasis, while within the range of previous reports, tended to increase over time. Patients with PsA had higher burdens of specific comorbid diseases than those with PsV, especially at a comparatively early age.
INTRODUCTION
Psoriasis, a systemic and inflammatory dermatological disease, affects an estimated 2-3% of the total population worldwide. 1, 2 The number of patients with psoriasis is generally considered to be relatively lower in Asians, but the exact prevalence is unknown. 3, 4 Psoriasis is complicated by psoriatic arthritis (PsA) in 7-40% of cases. 5 The majority of patients with PsA have psoriatic skin involvement, which typically precedes the onset of articular involvement. 6 Psoriasis is likely to be accompanied by other chronic medical conditions besides PsA, which complicates disease management. Various adverse outcomes such as obesity, hypertension, dyslipidemia, diabetes mellitus (DM) and atherosclerotic complications are associated with psoriasis. 7 Patients with PsA also have an increased risk of cardiovascular disease when compared with the normal population, and recent studies indicate that patients with severe psoriasis and PsA have higher mortality, primarily due to the increased risk of cardiovascular death. 8, 9 Despite the significant clinical and economic burden of psoriasis and PsA, there have been few comprehensive investigations into these diseases. In particular, previous studies characterizing psoriasis and PsA in Korean populations were mostly limited to surveys of single tertiary referral hospitals. The scarcity of nationwide data is a barrier to obtaining epidemiological information, including the age distribution and exact prevalence of psoriasis. Other nationwide studies on this issue were executed mostly on Caucasians, while such studies on Asian populations remain lacking; in addition, there is a general lack of published data on comorbidities, especially in patients with PsA. The present study aims to conduct an exploratory analysis of the Korean National Database to provide a descriptive assessment of psoriasis and PsA. We also have described demographics and important comorbidities of patients with PsA and psoriasis vulgaris (PsV) at baseline and during follow up.
METHODS

Study design
We selected a cohort of 855 003 people from 2002 through 2010 from the Korean National Health Insurance Database (NHID) in this retrospective, population-based study to analyze the epidemiology of psoriasis. We excluded 62 241 patients under 20 years of age to estimate the accurate prevalence of cerebro-cardiovascular (CV) comorbidities. The remaining 792 762 patients were censored by the presence of psoriasis, and 15 484 subjects with psoriasis were divided into cohorts with PsA or PsV. We compared the risks of CV morbidity and mortality as well as basic demographic data between the two groups. The flowchart of the study population selection is shown in Figure 1 . The study protocol was reviewed and approved by the institutional review board of Hanyang University Hospital.
Data sources
The Korean NHID is an administrative database which is already actively used as a tool for epidemiological studies of diverse medical conditions. In South Korea, all citizens have a responsibility to join the National Health Security System, conducted by the National Health Insurance Program, which covers all geographical regions in Korea. 10 The insurance claims database possesses vast information about inpatients and outpatients, including data on diagnoses from all primary to tertiary referral hospitals and the prescription drug claims. Therefore, the database provides data about the age, sex, diagnostic codes in the format of the International Classification of Disease, 10th Revision, Clinical Modification (ICD-10-CM), and dates of outpatient clinic visits for each individual.
Based on this information, we added a composite socioeconomic status (SES) variable using the average insurance premium for each household income and categorized individual household income into three groups (low, 0-20 percentile; moderate, 21-80 percentile; and high, 81-100 percentile).
Study population
The enrolled population profile in 2002 showed a bimodal peak of age distribution (5-14 and 30-44 years) and male predominance (58% vs 42%) (data not shown 
Ascertainment of diseases associated with psoriasis
We collected data for patients who had at least one claim with a principal or secondary diagnosis of CV disease (CVD) or CV risk factors, and all comorbidities were investigated through corresponding ICD-10 codes between 2002 and 2010. The primary end-point was defined as an incidence of one of the following major CVD: angina pectoris (ICD-10 codes: I20, I20.0, I20.1, I20.8 and I20.9), myocardial infarction (MI) (ICD-10 codes: I21, I22, I210-219 and I220-228), cerebral infarction (ICD-10 codes: I63, I630-639 and I6300-6390), cerebral hemorrhage (ICD-10 codes: I60, I600-609, I6000-6090, I61, I610-619 and I6100-6190) and peripheral artery disease (ICD-10 codes: I70, I70.0, I70.2, I70.8, I70.9, I79.2 and I79.8).
The secondary end-point included the composite incidence of CV risk factors such as hypertension (ICD-10 codes: I10-15, I100-150 and I1000-1500), type 2 DM (ICD-10 codes: E10-15, E100-150 and E1000-1500) and dyslipidemia (ICD-10 codes: E78, E780-789 and E7800-7890), as well as CV or all-cause induced mortality. All end-points were referred to as new events which developed in the post-index year, and the other diseases confirmed before or during the year when PsA or PsV was diagnosed were considered baseline variables.
Statistical analysis
The total number of psoriasis-coded cases identified yearly from 2002 to 2010 and the annual event rates per 100 000 patients were obtained by dividing the prevalence of each year by the total number of insured subjects in the same year. To calculate incidence, the difference between the prevalence at Figure 1 . Flowchart of the study. two time points was calculated. Furthermore, we computed the ratio of event rates for the number of comorbidities in the PsA population versus the PsV population using raw data from the NHID. Categorical variables were reported as count (percentage) and Pearson v 2 -tests were used to compare these variables between patients with PsA and PsV. We also utilized the log-rank test for univariate analysis and Cox regression analysis for age-sex adjustment to examine delicate patterns of comorbidities. Specifically, we estimated the age-stratified prevalence of comorbidities and mortality in subjects aged 20-39, 40-59 and 60 years or more. The results were expressed as a hazard ratio (HR) with a 95% confidence interval (CI) and P-value. All tests were two-tailed, and P < 0.05 was considered statistically significant. All statistical analyses were performed using the SAS version 9.3 statistical package (SAS Institute, Cary, NC, USA).
RESULTS
Overall psoriasis epidemiology
The annual prevalence rate (cases per 100 000 population) of psoriasis from 2002 to 2010 is summarized in Figure 2 (a). The reported prevalence of psoriasis gradually increased and peaked in 2008 (464.0). Since then, it has slightly decreased and was 453.5 in 2010. However, the general pattern of prevalence during the study period increased. The total number of new physician-diagnosed cases of psoriasis for each year is shown in Figure 2 (b). The yearly incidence of psoriasis fluctuated between 2003 and 2010 and tended to decrease from 252.7 to 212.6. When stratifying patients according to age with 5-year gap, patients in their 40s comprised the largest group of patients with psoriasis ( Fig. 2c) .
Baseline characteristics of patients with PsA and PsV
Over 9 years (2002-2010), the prevalence of PsA was 10.8% of the entire psoriatic cohort and the average incidence of PsA presented a distinct age distribution, showing a peak in the 70s. This was in contrast to the distribution of PsV, which showed a bimodal peak in the late 20s and 70s (Fig. 3) . Table 1 shows the baseline characteristics of subjects with PsA and PsV. Among 15 484 psoriatic patients over 20 years of age, 1888 (12.19%) patients with PsA were enrolled. The PsV cohort had a higher proportion of patients in the 20-39-year age range group than the PsA cohort (35.2% vs 11.6%). Of the patients with PsA, 47.19% were over 60 years, while only 23.54% of patients with PsV were in this age group. The PsA group included a higher proportion of female patients (69.23% vs 45.43%, P < 0.0001) and SES did not differ statistically between the two groups. Compared with the PsV cohort, the PsA cohort had higher baseline rates of hypertension, DM, dyslipidemia, angina pectoris, stoke and peripheral artery disease except for MI. Figure 2 . Trends in the (a) prevalence and (b) incidence of psoriasis and (c) age distribution of the study population reported in South Korea. Table 2 presents the incidence of several comorbidities in psoriasis and compares them between PsA and PsV patients. The proportion of patients with angina pectoris, peripheral artery disease and overall CVD was higher in subjects with PsA.
(a) (c) (b)
Composite CV risk factors were identified in 31.94% of participants with PsA compared with 24.32% of participants with PsV (P < 0.0001). The incidence of hypertension, DM and dyslipidemia was similar to the incidence of global CVD risk factors. CV mortality was seen in 1.22% of patients with PsA and 0.71% of patients with PsV, while all-cause mortality was demonstrated in 5.56% of the PsA cohort and 3.8% of the PsV cohort (P = 0.0191, 0.0003, respectively).
In univariate logistic regression analysis, patients with PsA tended to have significantly higher risks of numerous CVD, CV risk factors, CV death and all-cause death, which is consistent with the results presented in Table 2 . After further adjusting for age and sex, dyslipidemia remained significantly associated with PsA (HR, 1.185; 95% CI, 1.049-1.338) ( Table 3) .
When stratified by age at diagnosis, the PsA group had a higher risk of stroke, hypertension and dyslipidemia than the PsV group among patients aged 20-39 years (HR, 4.773 for stroke, 1.5 for composite CV risk factors, 2.27 for hypertension and 1.501 for dyslipidemia). In patients aged 40-59 years, a lower risk of DM was observed in the PsA cohort (HR, 0.726) and there was no significant association with CVD, CV risk factors or mortality in subjects older than 60 years (Table 4) .
DISCUSSION
We identified psoriatic cases from a database of 855 003 nonselected individuals enlisted in the Korean NHID and found an average annual prevalence of 0.42% during the 9-year period between 2002 and 2010. An annualized disease prevalence well under 1% was also found in other Asian countries: for example, the prevalence of psoriasis was 0.19% in Taiwan and 0.34% in Japan. 3, 11 The diversity of the index could be explained by geographical and ethnic differences, including differential distribution of human leukocyte antigen haplotypes in the Korean population. It may also be due to discrepancies in the application of diagnostic criteria for psoriasis or PsA. In this population-based study, we described trends in the prevalence and incidence of psoriasis over time and demonstrated that the prevalence of psoriasis increased in Korea, though the incidence tended to decrease. A previous study indicated an increasing trend in the prevalence of psoriasis between 1979 12 Similarly, another study reported that the incidence of psoriasis increased constantly over time. 13 The reasons for these changes in prevalence and incidence are unknown, but could include a true transition in these indices, alterations in lifestyle and environmental factors, an increased awareness of the disease and changes in patterns of diagnosis. The gradual retardation in the rate of population growth in Korea may also influence the incidence results. According to cohort studies, the PsA prevalence varies from 10% to 20%. [14] [15] [16] [17] [18] The 10.8% PsA prevalence in psoriatic patients that we found in this study was similar to or slightly lower than previous reports. The PsA population was characterized by a peak incidence in the 70s age group, which differed from the bimodal distribution of PsV, which peaked in the late 20s and 70s. Previous studies based on Caucasian populations have demonstrated that the prevalence of psoriasis decreases notably in patients over 70 years of age. 19, 20 In contrast, the mean 1-year prevalence peaked in Taiwanese patients aged 70 years and older, regardless of sex. 3 According to epidemiological data derived from a European population, the mean annual incidence or prevalence rate of PsA was highest in the age group from 40 to 60 years, which was comparatively lower than the peak incidence age group of the 70s. 21, 22 The elevated incidence of psoriasis and PsA in older age may be explained in part by higher utilization of the NHID at older ages. This may also have to do with structural characteristics of this cohort model, which evaluate one person in one dimension and follow the members over time as they age and die. These results may imply that elderly Korean psoriatic patients are less likely to go into remission; alternatively, elderly individuals in Korea may be at higher risk for developing new-onset psoriasis or PsA. Interestingly, the proportion of female patients was higher in the PsA group than in the PsV group. Among previous studies estimating the incidence of PsA, the male : female ratio varied significantly (median, 0.9; range, 0.4-1.3). 23 A study to determine the national prevalence of psoriasis and palmoplantar pustulosis in Japan demonstrated 53.0% of male predominance in the PsA group which was not in accordance with our data. 11 In the present study, the elderlyfocused age distribution of PsA could be attributed to a comparatively longer lifespan in women, who tended to have PsA more than PsV. As mentioned above, the discrepancy may be also explained by unique demographic properties of the Korean population. Studies have shown an increased risk of CV morbidity in patients with psoriasis and PsA. [7] [8] [9] Specifically, severe psoriasis is related to an increased risk of major CV events and CV death in over 50% of cases, above and beyond the mortality associated with traditional CV risk factors. 24 However, the majority of these findings were deduced from patients with psoriasis who were not assessed for inflammatory arthritis; therefore, the link between PsA and CVD is less defined. Only a few studies have been carried out in Western countries, and these do not reflect the exact association between these variables in Asian populations including Korean patients, especially as we lack nationwide cohort studies. [25] [26] [27] [28] Consequently, the role of joint inflammation in explaining the increased risk of CVD in patients with psoriasis remains unclear. This study utilized the Korean NHID database to compare the risk of developing comorbid diseases in patients with PsA and PsV. In the index year, patients with PsA reported a greater prevalence of overall comorbid diagnoses, with notably higher rates of hypertension, DM, dyslipidemia, angina pectoris and cerebral infarction than patients with PsV. The leading comorbid condition in PsA was hypertension, with an estimated prevalence of 33.42%. This was comparable with previous studies identifying a range of 25-49%, but was higher than the result of a hospital-based study in Korea. [28] [29] [30] [31] This outcome may be due to the relatively older age in the PsA cohort, as these patients are more susceptible to various chronic disorders or concomitant use of drugs. Our study showed that PsA patients have a higher risk for angina pectoris, peripheral artery disease, global CV risk factors, CV death and all-cause death than PsV patients. According to Parisi et al., 32 PsA patients had 36% more major CV events than patients with PsV. We demonstrated that the incidence of dyslipidemia, a CV risk factor, was 18.5% greater in patients with PsA than in patients with PsV after adjustment. Patients with PsA or PsV are known to share common complications such as hypertension, dyslipidemia, DM or insulin resistance and CVD. In particular, psoriasis and PsA have been associated with conventional CV risk factors, overt CVD and CV death, as well as progression in atherosclerotic disease from endothelial dysfunction to stenosis of the carotid or coronary arteries. 25 Moreover, an immunological approach for these connections hypothesizes that body composition is interrupted in psoriatic patients. This approach suggests that an excessive accumulation of abdominal fat is observed in PsA patients, making them more vulnerable to obesity-related complications such as metabolic syndrome and CVD than those with PsV. 33 Subsequent data including information on body mass index (BMI) may be helpful to prove these findings. On the other hand, a previous systematic published work review did not show a strong increase in CV mortality in patients with psoriasis or PsA and suggested that further prospective studies are needed to confirm the direct relationship between psoriatic lesions and CV problems. In addition, the potential role of other possible confounders including diet, physical activity and genetic factors requires further study. 34 After the stratification of age groups, the 20-39-year group showed PsA predominance in the categories of stroke, hypertension and dyslipidemia. Overall, Korean patients aged 65-74 years accounted for more than 30% of all strokes and those under 44 years of age accounted for only 6.5% of all strokes. 35 Another Korean epidemiological study demonstrated that the median age of metabolic syndrome was 46 years in men and 44 years in women. 36 The full spectrum of stroke or metabolic syndrome has not been formally studied in patients with PsA. However, it is notable that patients with PsA showed higher incidence of CVD and CV risk factors than patients with PsV in comparatively young adults, implying an additive role of arthritis in early CV problems. To the best of our knowledge, this is the first report analyzing the risk of incidental CVD according to age in psoriatic patients with or without arthritis. The discrepancy in the incidence of comorbidities between PsA and PsV may be explained by the bio-immunological elements mentioned above. In addition, early development of psoriasis (age of onset before 40 years) has been associated with more widespread disease. These patients tend to report a greater extent of psoriasis and are generally more affected by comorbidities including PsA than those with mild involvement. 14, 37 The practise of utilizing CVD risk assessment or management tools should be emphasized to prevent such comorbidities, especially given the relatively young age of patients with PsA.
There are several limitations of the present study which should be taken into consideration. First, the epidemiological data with prevalence of comorbidities was assessed by diagnostic coding from an administrative claims database. Therefore, misclassification and omission of several variables might have caused bias among our cohort. Second, we did not evaluate the exact degree of associations between psoriatic lesions and medical comorbidities because of confounders such as BMI, habitual behaviors or treatment. Finally, data regarding the clinical severity of psoriasis, such as the affected surface area and Psoriasis Area and Severity Index, were not available in our analyses.
Despite these limitations, this Korean nationwide cohort study has several strengths compared with previously reported results in Western (especially European) countries. In terms of epidemiology, we demonstrated that the prevalence of psoriasis increased in Korea, though the incidence tended to decrease which is different from the result of European countries showing constant increase in prevalence and incidence of psoriasis. The 10.8% PsA prevalence among psoriasis in this study was slightly lower than the previous Western reports. In contrast to demographic data derived from a European population showing the mean annual prevalence or prevalence rate of PsA was highest in the age group from 40 to 60 years, our data was characterized by a peak incidence in the 70s age group. The male : female ratio in PsA was also different from several Caucasian researches. Especially, we analyzed the risk of incidental CVD according to age in psoriatic patients with or without arthritis which was not previously reported.
In conclusion, this study is the first trial to evaluate the epidemiology of psoriasis and compare the development of CV comorbidities between PsA and PsV patients through the Korean NHID. Our findings provide demographic information on psoriasis in Korea and support the notion that PsA is a potentially crucial risk factor for CVD.
